List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/395195/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sialic acid-mediated photochemotherapy enhances infiltration of CD8+ T cells from tumor-draining lymph nodes into tumors of immunosenescent mice. Acta Pharmaceutica Sinica B, 2023, 13, 425-439.	12.0	4
2	Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives. Drug Delivery and Translational Research, 2022, 12, 647-661.	5.8	3
3	Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions. International Journal of Pharmaceutics, 2022, 612, 121365.	5.2	7
4	PEGylated nanoemulsions containing 1,2-distearoyl-sn-glycero-3-phosphoglycerol induced weakened accelerated blood clearance phenomenon. Drug Delivery and Translational Research, 2022, 12, 2569-2579.	5.8	3
5	Discovery in polyethylene glycol immunogenicity: The characteristic of intergenerational inheritance of anti-polyethylene glycol IgG. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 172, 89-100.	4.3	3
6	The Fate of Sialic Acid and PEG Modified Epirubicin Liposomes in Aged versus Young Cells and Tumor Mice Models. Pharmaceutics, 2022, 14, 545.	4.5	8
7	A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions. Journal of Controlled Release, 2022, 343, 657-671.	9.9	14
8	Neutrophils as emerging immunotherapeutic targets: Indirect treatment of tumors by regulating the tumor immune environment based on a sialic acid derivative-modified nanocomplex platform. International Journal of Pharmaceutics, 2022, 620, 121684.	5.2	9
9	Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy. Biomaterials, 2022, 283, 121415.	11.4	25
10	Polysialic Acid Self-assembled Nanocomplexes for Neutrophil-Based Immunotherapy to Suppress Lung Metastasis of Breast Cancer. AAPS PharmSciTech, 2022, 23, 109.	3.3	4
11	Sialic Acid Conjugate–Modified Liposomal Dexamethasone Palmitate Targeting Neutrophils for Rheumatoid Arthritis Therapy: Influence of Particle Size. AAPS PharmSciTech, 2021, 22, 16.	3.3	13
12	Photodynamic/ photothermal therapy enhances neutrophil-mediated ibrutinib tumor delivery for potent tumor immunotherapy: More than one plus one?. Biomaterials, 2021, 269, 120652.	11.4	27
13	Influence of Dose on Neutrophil-Mediated Delivery of Nanoparticles for Tumor-Targeting Therapy Strategies. AAPS PharmSciTech, 2021, 22, 89.	3.3	2
14	A new application of monosialotetrahexosylganglioside in pharmaceutics: preparation of freeze-thaw-resistant coenzyme Q10 emulsions. European Journal of Pharmaceutical Sciences, 2021, 159, 105701.	4.0	4
15	Sequential administration of sialic acid-modified liposomes as carriers for epirubicin and zoledronate elicit stronger antitumor effects with reduced toxicity. International Journal of Pharmaceutics, 2021, 602, 120552.	5.2	15
16	Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. Acta Biomaterialia, 2021, 134, 702-715.	8.3	28
17	Evaluation of the Antitumor Effect and Immune Response of Micelles Modified with a Polysialic Acid-d-α-Tocopheryl Polyethylene Glycol 1000 Succinate Conjugate. AAPS PharmSciTech, 2021, 22, 223. 	3.3	5
18	Dual targeting single arrow: Neutrophil-targeted sialic acid-modified nanoplatform for treating comorbid tumors and rheumatoid arthritis. International Journal of Pharmaceutics, 2021, 607, 121022.	5.2	5

#	Article	IF	CITATIONS
19	Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation. Journal of Controlled Release, 2021, 337, 612-627.	9.9	19
20	Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy. Journal of Controlled Release, 2021, 337, 393-406.	9.9	34
21	Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency. Asian Journal of Pharmaceutical Sciences, 2020, 15, 365-373.	9.1	13
22	Correlation between mouse age and human age in anti-tumor research: Significance and method establishment. Life Sciences, 2020, 242, 117242.	4.3	98
23	Accelerated Blood Clearance of Nanoemulsions Modified with PEG-Cholesterol and PEG-Phospholipid Derivatives in Rats: The Effect of PEG-Lipid Linkages and PEG Molecular Weights. Molecular Pharmaceutics, 2020, 17, 1059-1070.	4.6	24
24	Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages – A promising cancer immunotherapy. International Journal of Pharmaceutics, 2020, 590, 119929.	5.2	31
25	Development of a nattokinase–polysialic acid complex for advanced tumor treatment. European Journal of Pharmaceutical Sciences, 2020, 145, 105241.	4.0	14
26	Polysialic Acid Modified Liposomes for Improving Pharmacokinetics and Overcoming Accelerated Blood Clearance Phenomenon. Coatings, 2020, 10, 834.	2.6	5
27	The Contribution of PEG Molecular Weights in PEGylated Emulsions to the Various Phases in the Accelerated Blood Clearance (ABC) Phenomenon in Rats. AAPS PharmSciTech, 2020, 21, 300.	3.3	9
28	Effects of Uncleavable and Cleavable PEG-Lipids with Different Molecular Weights on Accelerated Blood Clearance of PEGylated Emulsions in Beagle Dogs. AAPS PharmSciTech, 2020, 21, 106.	3.3	6
29	Sialic acid-conjugate modified liposomes targeting neutrophils for improved tumour therapy. Biomaterials Science, 2020, 8, 2189-2201.	5.4	37
30	Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents. Asian Journal of Pharmaceutical Sciences, 2019, 14, 265-274.	9.1	149
31	A Sialylated-Bortezomib Prodrug Strategy Based on a Highly Expressed Selectin Target for the Treatment of Leukemia or Solid Tumors. Pharmaceutical Research, 2019, 36, 176.	3.5	8
32	Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy. International Journal of Pharmaceutics, 2019, 571, 118706.	5.2	30
33	Exhausting tumor associated macrophages with sialic acid-polyethyleneimine-cholesterol modified liposomal doxorubicin for enhancing sarcoma chemotherapy. International Journal of Pharmaceutics, 2019, 558, 187-200.	5.2	17
34	Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy. AAPS PharmSciTech, 2019, 20, 188.	3.3	23
35	Neutrophil-Mediated Delivery of Dexamethasone Palmitate-Loaded Liposomes Decorated with a Sialic Acid Conjugate for Rheumatoid Arthritis Treatment. Pharmaceutical Research, 2019, 36, 97.	3.5	42
36	Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. Acta Biomaterialia, 2019, 92, 184-195.	8.3	69

#	Article	IF	CITATIONS
37	Targeted Delivery of miRNA 155 to Tumor Associated Macrophages for Tumor Immunotherapy. Molecular Pharmaceutics, 2019, 16, 1714-1722.	4.6	41
38	Targeted Delivery of Zoledronate to Tumor-Associated Macrophages for Cancer Immunotherapy. Molecular Pharmaceutics, 2019, 16, 2249-2258.	4.6	64
39	Effect of Kupffer cells depletion on ABC phenomenon induced by Kupffer cells-targeted liposomes. Asian Journal of Pharmaceutical Sciences, 2019, 14, 455-464.	9.1	12
40	Effects of stability of PEGylated micelles on the accelerated blood clearance phenomenon. Drug Delivery and Translational Research, 2019, 9, 66-75.	5.8	15
41	Murine RAW264.7 cells as cellular drug delivery carriers for tumor therapy: a good idea?. Cancer Chemotherapy and Pharmacology, 2019, 83, 361-374.	2.3	9
42	Comparison among different "revealers―in the study of accelerated blood clearance phenomenon. European Journal of Pharmaceutical Sciences, 2018, 114, 210-216.	4.0	6
43	Polysialic acid-polyethylene glycol conjugate-modified liposomes as a targeted drug delivery system for epirubicin to enhance anticancer efficiency. Drug Delivery and Translational Research, 2018, 8, 602-616.	5.8	19
44	The accelerated blood clearance phenomenon of PEGylated nanoemulsion upon cross administration with nanoemulsions modified with polyglycerin. Asian Journal of Pharmaceutical Sciences, 2018, 13, 44-53.	9.1	14
45	Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate. Drug Delivery and Translational Research, 2018, 8, 1-11.	5.8	23
46	Preparation and toxicity evaluation of a novel nattokinase-tauroursodeoxycholate complex. Asian Journal of Pharmaceutical Sciences, 2018, 13, 173-182.	9.1	9
47	Redox- and pH-Sensitive Glycan (Polysialic Acid) Derivatives and F127 Mixed Micelles for Tumor-Targeted Drug Delivery. Molecular Pharmaceutics, 2018, 15, 5534-5545.	4.6	19
48	Novel Self-Assembled Ibrutinib-Phospholipid Complex for Potently Peroral Delivery of Poorly Soluble Drugs with pH-Dependent Solubility. AAPS PharmSciTech, 2018, 19, 3571-3583.	3.3	18
49	Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration. AAPS PharmSciTech, 2018, 19, 3210-3218.	3.3	12
50	Use of Dual-Ligand Modification in Kupffer Cell-Targeted Liposomes To Examine the Contribution of Kupffer Cells to Accelerated Blood Clearance Phenomenon. Molecular Pharmaceutics, 2018, 15, 2548-2558.	4.6	20
51	Neutrophil-mediated delivery of pixantrone-loaded liposomes decorated with poly(sialic) Tj ETQq1 1 0.784314 rg	gBT_/Overl	ock_10 Tf 50
52	Enhanced Opsonization-Independent Phagocytosis and High Response Ability to Opsonized Antigen–Antibody Complexes: A New Role of Kupffer Cells in the Accelerated Blood Clearance Phenomenon upon Repeated Injection of PEGylated Emulsions. Molecular Pharmaceutics, 2018, 15, 3755-3766.	4.6	13
53	Targeted delivery of pixantrone to neutrophils by poly(sialic acid)-p-octadecylamine conjugate modified liposomes with improved antitumor activity. International Journal of Pharmaceutics, 2018, 547, 315-329.	5.2	27
54	Nanoparticles for tumor immunotherapy. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 243-256.	4.3	92

#	Article	IF	CITATIONS
55	Production of highly concentrated oil-in-water emulsions using dual-channel microfluidization: Use of individual and mixed natural emulsifiers (saponin and lecithin). Food Research International, 2017, 96, 103-112.	6.2	58
56	A novel nanosuspension of andrographolide: Preparation, characterization and passive liver target evaluation in rats. European Journal of Pharmaceutical Sciences, 2017, 104, 13-22.	4.0	32
57	Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. International Journal of Pharmaceutics, 2017, 523, 203-216.	5.2	81
58	Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, <i>in vitro</i> , and <i>in vivo</i> characterization. Drug Development and Industrial Pharmacy, 2017, 43, 2016-2025.	2.0	10
59	The antitumor efficacy of docetaxel is enhanced by encapsulation in novel amphiphilic polymer cholesterol-coupled tocopheryl polyethylene glycol 1000 succinate micelles. Drug Delivery and Translational Research, 2017, 7, 642-653.	5.8	7
60	Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells. Oncology Letters, 2017, 14, 145-152.	1.8	28
61	Polysialic acid and pluronic F127 mixed polymeric micelles of docetaxel as new approach for enhanced antitumor efficacy. Drug Development and Industrial Pharmacy, 2017, 43, 1827-1835.	2.0	13
62	Fabrication of β-carotene nanoemulsion-based delivery systems using dual-channel microfluidization: Physical and chemical stability. Journal of Colloid and Interface Science, 2017, 490, 328-335.	9.4	92
63	The effect of monosialylganglioside mix modifying the PEGylated liposomal epirubicin on the accelerated blood clearance phenomenon. Asian Journal of Pharmaceutical Sciences, 2017, 12, 134-142.	9.1	11
64	Effects of complement inhibition on the ABC phenomenon in rats. Asian Journal of Pharmaceutical Sciences, 2017, 12, 250-258.	9.1	16
65	Mixed PEGylated surfactant modifying system decrease the accelerated blood clearance phenomenon of nanoemulsions in rats. Asian Journal of Pharmaceutical Sciences, 2017, 12, 28-36.	9.1	8
66	Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid–octadecylamine conjugate. European Journal of Pharmaceutical Sciences, 2016, 93, 177-183.	4.0	32
67	Polysialic acid-modifying liposomes for efficient delivery of epirubicin, in-vitro characterization and in-vivo evaluation. International Journal of Pharmaceutics, 2016, 515, 449-459.	5.2	25
68	The 12-3-12 cationic gemini surfactant as a novel gastrointestinal bioadhesive material for improving the oral bioavailability of coenzyme Q10 naked nanocrystals. Drug Development and Industrial Pharmacy, 2016, 42, 2044-2054.	2.0	9
69	Are PEGylated liposomes better than conventional liposomes? A special case for vincristine. Drug Delivery, 2016, 23, 1092-1100.	5.7	51
70	Preparation and evaluation of PEGylated phospholipid membrane coated layered double hydroxide nanoparticles. Asian Journal of Pharmaceutical Sciences, 2016, 11, 396-403.	9.1	12
71	Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs. International Journal of Nanomedicine, 2015, 10, 3533.	6.7	28
72	Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Delivery, 2015, 22, 598-607.	5.7	50

#	Article	IF	CITATIONS
73	Multifunctional liposomes constituting microneedles induced robust systemic and mucosal immunoresponses against the loaded antigens via oral mucosal vaccination. Vaccine, 2015, 33, 4330-4340.	3.8	54
74	A review on phospholipids and their main applications in drug delivery systems. Asian Journal of Pharmaceutical Sciences, 2015, 10, 81-98.	9.1	682
75	Improvement of pharmacokinetic and antitumor activity of layered double hydroxide nanoparticles by coating with PEGylated phospholipid membrane. International Journal of Nanomedicine, 2014, 9, 4867.	6.7	16
76	Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system. International Journal of Nanomedicine, 2014, 9, 2307.	6.7	47
77	The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient. International Journal of Nanomedicine, 2014, 9, 3611.	6.7	24
78	Tolerance-like innate immunity and spleen injury: a novel discovery via the weekly administrations and consecutive injections of PEGylated emulsions. International Journal of Nanomedicine, 2014, 9, 3645.	6.7	12
79	Using procedure of emulsification–lyophilization to form lipid A-incorporating cochleates as an effective oral mucosal vaccine adjuvant-delivery system (VADS). International Journal of Pharmaceutics, 2014, 468, 39-49.	5.2	34
80	Application of sialic acid/polysialic acid in the drug delivery systems. Asian Journal of Pharmaceutical Sciences, 2014, 9, 75-81.	9.1	39
81	Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 194-206.	4.3	79
82	Coencapsulation of epirubicin and metformin in PEGylated liposomes inhibits the recurrence of murine sarcoma S180 existing CD133+ cancer stem-like cells. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 88, 737-745.	4.3	36
83	The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid–octadecylamine conjugate. Biomaterials, 2014, 35, 5216-5225.	11.4	56
84	Progress involving new techniques for liposome preparation. Asian Journal of Pharmaceutical Sciences, 2014, 9, 176-182.	9.1	106
85	A noticeable phenomenon: Thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into rats. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 744-751.	4.3	19
86	Preparation of berberine hydrochloride long-circulating liposomes by ionophore A23187-mediated ZnSO4 gradient method. Asian Journal of Pharmaceutical Sciences, 2013, 8, 261-266.	9.1	18
87	Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. International Journal of Nanomedicine, 2013, 8, 1257.	6.7	32
88	A frustrating problem: Accelerated blood clearance of PEGylated solid lipid nanoparticles following subcutaneous injection in rats. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 506-513.	4.3	50
89	Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles. International Journal of Nanomedicine, 2012, 7, 2891.	6.7	46
90	Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals. International Journal of Nanomedicine, 2012, 7, 5733.	6.7	139

Υιμμι Deng

#	Article	IF	CITATIONS
91	Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats. European Journal of Pharmaceutical Sciences, 2012, 45, 539-545.	4.0	44
92	Effects of pHâ€Sensitive Groups on Poly(ethylene oxide)â€ <i>block</i> â€poly(ϵâ€caprolactone) Block Copolymer Micelles Used as Drug Carriers. Macromolecular Chemistry and Physics, 2011, 212, 2511-2521.	2.2	11
93	Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. Journal of Controlled Release, 2008, 130, 238-245.	9.9	97